Now showing items 1-1 of 1

    • Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma 

      Borrell Bilbao, José Ignacio; Teixidó i Closa, Jordi; Puig de la Bellacasa Cazorla, Raimon; Roué, Gaël; Balsas, P.; Esteve-Arenys, A.; Roldán, J.; Jiménez, L.; Rodríguez, V.; Valero, J. G.; Chamorro-Jorganes, A.; Matas-Céspedes, A.; Moros, A.; Martínez, A.; Campo, E.; Sáez-Borderías, A.; Pérez-Galán, P.; Colomer, D. (Journal of Hematology & Oncology. Vol.10, n.80 (2017), 2017-03)
      Background Pharmacological inhibition of B cell receptor (BCR) signaling has recently emerged as an effective approach in a wide range of B lymphoid neoplasms. However, despite promising clinical activity ...